Artivion Inc. is a global company that develops, produces, and supplies medical devices and implantable human tissues. Its product range includes BioGlue, a polymer derived from bovine blood protein combined with a cross-linking agent, utilized in cardiac, vascular, neurological, and pulmonary surgical applications. The company also offers heart preservation services and the PhotoFix bovine pericardial patch, in addition to E-vita Open Plus and E-vita Open Neo devices. For the treatment of aortic vascular conditions, Artivion provides specialized stent graft systems. These include E-xtra design engineering systems for aortic vascular diseases, E-nside as an off-the-shelf solution for thoraco-abdominal disease, E-vita THORACIC 3G for endovascular repair of thoracic aortic aneurysms, E-nya for minimally invasive repair of descending aorta lesions, and the E-tegra system for abdominal aortic aneurysms. Furthermore, its offerings address peripheral and renal artery treatments with the E-ventus BX balloon-expandable stent graft and the E-liac system for aneurysmal iliac arteries and their side branches. The company's diverse portfolio extends to synthetic vascular grafts for use in open aortic and peripheral vascular surgeries, PerClot (an absorbable powdered hemostat for surgical procedures), and cardiac laser therapy products for angina management. Preservation services include CryoVein for femoral veins and CryoArtery for femoral arteries. Artivion also manufactures On-X prosthetic aortic and mitral heart valves, along with the On-X ascending aortic prosthesis. Supplementary devices feature CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures designed for mitral chordal replacement, as well as ascyrus medical dissection stents. Beyond products, the company offers pyrolytic carbon coating services to other medical device manufacturers. Artivion Inc. serves a broad client base, including physicians, hospitals, other healthcare facilities, and specialists such as cardiac, vascular, thoracic, and general surgeons. Established in 1984 and headquartered in Kennesaw, Georgia, the company adopted the name Artivion Inc. in January 2022, having previously operated as CryoLife, Inc.
前收盘价
US$21.79
+US$0.53 · +2.49%
盘后
US$21.79
US$0.00 · 0.00%
10月12日 16:00 ET
盘中时间采用ET。市场数据可能有所延迟。
Artivion Inc. is a global company that develops, produces, and supplies medical devices and implantable human tissues. Its product range includes BioGlue, a polymer derived from bovine blood protein combined with a cross-linking agent, utilized in cardiac, vascular, neurological, and pulmonary surgical applications. The company also offers heart preservation services and the PhotoFix bovine pericardial patch, in addition to E-vita Open Plus and E-vita Open Neo devices. For the treatment of aortic vascular conditions, Artivion provides specialized stent graft systems. These include E-xtra design engineering systems for aortic vascular diseases, E-nside as an off-the-shelf solution for thoraco-abdominal disease, E-vita THORACIC 3G for endovascular repair of thoracic aortic aneurysms, E-nya for minimally invasive repair of descending aorta lesions, and the E-tegra system for abdominal aortic aneurysms. Furthermore, its offerings address peripheral and renal artery treatments with the E-ventus BX balloon-expandable stent graft and the E-liac system for aneurysmal iliac arteries and their side branches. The company's diverse portfolio extends to synthetic vascular grafts for use in open aortic and peripheral vascular surgeries, PerClot (an absorbable powdered hemostat for surgical procedures), and cardiac laser therapy products for angina management. Preservation services include CryoVein for femoral veins and CryoArtery for femoral arteries. Artivion also manufactures On-X prosthetic aortic and mitral heart valves, along with the On-X ascending aortic prosthesis. Supplementary devices feature CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures designed for mitral chordal replacement, as well as ascyrus medical dissection stents. Beyond products, the company offers pyrolytic carbon coating services to other medical device manufacturers. Artivion Inc. serves a broad client base, including physicians, hospitals, other healthcare facilities, and specialists such as cardiac, vascular, thoracic, and general surgeons. Established in 1984 and headquartered in Kennesaw, Georgia, the company adopted the name Artivion Inc. in January 2022, having previously operated as CryoLife, Inc.
日内区间
当前US$21.79
52周区间
当前US$21.79
盘中时间采用ET。市场数据可能有所延迟。
Artivion Inc. is a global company that develops, produces, and supplies medical devices and implantable human tissues. Its product range includes BioGlue, a polymer derived from bovine blood protein combined with a cross-linking agent, utilized in cardiac, vascular, neurological, and pulmonary surgical applications. The company also offers heart preservation services and the PhotoFix bovine pericardial patch, in addition to E-vita Open Plus and E-vita Open Neo devices. For the treatment of aortic vascular conditions, Artivion provides specialized stent graft systems. These include E-xtra design engineering systems for aortic vascular diseases, E-nside as an off-the-shelf solution for thoraco-abdominal disease, E-vita THORACIC 3G for endovascular repair of thoracic aortic aneurysms, E-nya for minimally invasive repair of descending aorta lesions, and the E-tegra system for abdominal aortic aneurysms. Furthermore, its offerings address peripheral and renal artery treatments with the E-ventus BX balloon-expandable stent graft and the E-liac system for aneurysmal iliac arteries and their side branches. The company's diverse portfolio extends to synthetic vascular grafts for use in open aortic and peripheral vascular surgeries, PerClot (an absorbable powdered hemostat for surgical procedures), and cardiac laser therapy products for angina management. Preservation services include CryoVein for femoral veins and CryoArtery for femoral arteries. Artivion also manufactures On-X prosthetic aortic and mitral heart valves, along with the On-X ascending aortic prosthesis. Supplementary devices feature CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures designed for mitral chordal replacement, as well as ascyrus medical dissection stents. Beyond products, the company offers pyrolytic carbon coating services to other medical device manufacturers. Artivion Inc. serves a broad client base, including physicians, hospitals, other healthcare facilities, and specialists such as cardiac, vascular, thoracic, and general surgeons. Established in 1984 and headquartered in Kennesaw, Georgia, the company adopted the name Artivion Inc. in January 2022, having previously operated as CryoLife, Inc.
日内区间
当前US$21.79
52周区间
当前US$21.79
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目(USD) | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 4.41亿 USD | 3.89亿 USD | 3.54亿 USD | 3.14亿 USD | 2.99亿 USD |
| 销货成本 | 1.71亿 USD | 1.4亿 USD | 1.25亿 USD | 1.11亿 USD | 1.01亿 USD |
| 毛利 | 2.7亿 USD | 2.49亿 USD | 2.29亿 USD | 2.03亿 USD | 1.98亿 USD |
| 研究与开发 | 3099.1万 USD | 2845.2万 USD | 2870.7万 USD | 3887.9万 USD | 3554.6万 USD |
| 销售、一般及管理费用 | 2.13亿 USD | 1.92亿 USD | 2.09亿 USD | 1.57亿 USD | 1.7亿 USD |
| 营业费用 | 2.44亿 USD | 2.1亿 USD | 2.23亿 USD | 1.96亿 USD | 1.89亿 USD |
| 利息收入 | 76.3万 USD | 146.7万 USD | 107.7万 USD | 14.7万 USD | 7.9万 USD |
| 利息支出 | 2658.2万 USD | 3427.7万 USD | 2529.9万 USD | 1822.4万 USD | 1688.7万 USD |
| 折旧和摊销 | 2245.8万 USD | 2420.5万 USD | 2307.6万 USD | 2244.2万 USD | 2397.7万 USD |
| 营业利润 | 2674.5万 USD | 3887.4万 USD | 574.2万 USD | 620.1万 USD | 811.7万 USD |
| 净利润 | 976.8万 USD | −1335.9万 USD | −3069万 USD | −1919.2万 USD | −1483.4万 USD |
公司数据更新于 2026年10月13日。
已公布业绩及可用的市场共识预期。
已公布业绩及可用的市场共识预期。
第三方分析师预期可能变化,并非 GoAI 建议。
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI3949.55万0.00%2.3万亿 USD0.03%US$381.57-0.10%
iShares Russell 2000 ETFIWM2531.49万0.03%787.4亿 USD0.19%US$277.9-0.37%
Vanguard Extended Market ETFVXF1340.47万0.01%954亿 USD0.05%US$233.52-0.63%
State Street SPDR Portfolio S&P 600 Small Cap ETFSPSM950.54万0.06%157.12亿 USD0.03%US$53.42-0.06%
iShares Russell 2000 Growth ETFIWO897.57万0.06%139.17亿 USD0.24%US$353.71-0.86%
Dimensional - US Small Cap ETFDFAS739.51万0.02%338.69亿 USD0.31%US$78.17-0.23%
Vanguard Russell 2000 ETFVTWO709.13万0.04%180亿 USD0.06%US$112.27-0.35%
State Street SPDR S&P 600 Small Cap Growth ETFSLYG604.42万0.13%48.09亿 USD0.15%US$108.33-0.22%
Vanguard Morningstar Total Stock Market ETFVTI
iShares Russell 2000 ETFIWM
Vanguard Extended Market ETFVXF
State Street SPDR Portfolio S&P 600 Small Cap ETFSPSM
iShares Russell 2000 Growth ETFIWO
Dimensional - US Small Cap ETFDFAS
Vanguard Russell 2000 ETFVTWO
State Street SPDR S&P 600 Small Cap Growth ETFSLYGAI 生成内容及延迟市场数据仅供信息与教育用途,不构成投资建议。